According to the Ethiopian ART national guidelines which have been revised with a supplement after the country’s adoption of WHO’s “Test and treat”, CD4 testing is required for all patients at baseline and to determine eligibility and follow up of opportunistic infection prophylaxis as well as for monitoring immunologic failure where viral load monitoring is not accessible/possible [4]. This evidence concerns the gene CD4 and Opportunistic infection.